Arformoterol Tartrate Inhalation Solution NDC 76204-026

NDC codes

FDA NDC Directory

Product NDC (as listed)76204-026Labeler and product segments. Claims need a package NDC.

Product NDC at billing width76204-0026Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
76204-026-01	76204002601	30 POUCH in 1 CARTON (76204-026-01) / 1 AMPULE in 1 POUCH / 2 mL in 1 AMPULEMarketed from Feb 27, 2023
76204-026-02	76204002602	60 POUCH in 1 CARTON (76204-026-02) / 1 AMPULE in 1 POUCH / 2 mL in 1 AMPULEMarketed from Feb 27, 2023
76204-026-55	76204002655	12 POUCH in 1 CARTON (76204-026-55) / 5 AMPULE in 1 POUCH / 2 mL in 1 AMPULEMarketed from Feb 27, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Arformoterol Tartrate Inhalation Solution
Generic name (nonproprietary): arformoterol tartrate inhalation solution
Active ingredients: Arformoterol tartrate — 15 ug/2mL
Dosage form: Solution
Route: Respiratory (Inhalation)
Labeler: Ritedose Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214736
Marketing start: Feb 27, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic beta2-Agonists (Mechanism)
Identifiers: Product ID 76204-026_459f97a4-5026-29d1-e063-6294a90a1a9aSPL ID 459f97a4-5026-29d1-e063-6294a90a1a9aSPL set ID ef524b4c-68d7-c464-e053-2a95a90a7f96RxCUI 668956UNII 5P8VJ2I235UPC 0376204026024, 0376204026017
Pharmacologic class: beta2-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N476204002601 followed by a unit qualifier and the quantity

Package 76204-0026-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 10, 2025.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE Arformoterol Tartrate Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: Arformoterol Tartrate Inhalation Solution is not inidcated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) Arformoterol Tartrate Inhalation Solution is not indicated to treat asthma. (1.2) 1.1 Maintenance Treatment of COPD Arformoterol Tartrate Inhalation Solution i…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)